Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
Community Search
Biophysics Working Group
Share |

CASSS announces the creation of a Biophysics Working Group. This group brings together scientists from across public and private sectors to foster collaboration and address unmet challenges in the application of biophysical methods to biologics research and development.

Who we are: The Biophysics Working Group has members from a variety of variety of different companies as well as academia and government labs. The group has an open enrollment policy, accepting any scientist at any level in either a public or private organization. We just ask that members of the group be willing to take an active role in improving the application of biophysical methods to biologics research and development. We welcome new scientists at any time, so please join the group and bring your ideas! To get involved, click here

What we do: We bring together scientists from across public and private sectors to foster collaboration and address unmet challenges in the application of biophysical methods to biologics research and development. As a diverse group of scientists with common interests and a common goal, we seek to further CASSS’ purpose to enable a global community of industry, academic and regulatory professionals to work together to resolve scientific challenges in the field of biopharmaceutical development and regulation. The group will work to execute and publish highly collaborative, non-proprietary studies focused on applications of biophysical methods.

How we do it: This group seeks to publish research results in leading scientific journals and share learnings in CASSS conferences worldwide. We seek to produce tangible results through execution of lab work and publication of results with clear scientific merit and industry-wide value. The timing of disclosures is expected to vary based on the scope and complexity of the project, but the group will work diligently to share learnings with the broader scientific community as quickly as possible.

The goals of the group are to provide guidance and best practices, support innovation and advance transformative ideas, and generally enhance the overall scientific dialogue through contributions in various publications and CASSS conferences around the world. This group also aligns with CASSS’ purpose to enable a global community of industry, academic and regulatory professionals to work together to resolve scientific challenges in the field of biopharmaceutical development and regulation.

Members of the former “HOS Consortium” have included: Amgen Inc., AbbVie, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Elion Labs, Genentech, a Member of the Roche Group, GlaxoSmithKline, Janssen, MedImmune, A member of the AstraZeneca Group, Pfizer, Inc., NIST, Sandoz, University of Delaware, University of Kansas, University of New Hampshire, and Yeshiva University. 

 

The group is currently soliciting proposals for collaborative research projects or other initiatives that will effectively leveraging capabilities across member organizations.

 

To get involved click here! 

 


Technical Decision-Making with Higher Order Structure Data Series (Published Dates 2015-2016)

Introductory Commentary

Gabrielson JP, Weiss WF 4th 2015. Technical decision-making with higher order structure data: starting a new dialogue. Journal of pharmaceutical sciences 104(4);1240-1245. 

Industry Case Studies

Gabrielson JP, Weiss WF 4th 2015. Technical decision-making with higher order structure data: starting a new dialogue. Journal of pharmaceutical sciences  104(4):1240-1245.

Arthur KK, Dinh N, Gabrielson JP 2015. Technical decision making with higher order structure data: utilization of differential scanning calorimetry to elucidate critical protein structural changes resulting from oxidation. Journal of pharmaceutical sciences  104(4):1548-1554.

Budyak IL, Doyle BL, Weiss WF 4th 2015. Technical decision-making with higher order structure data: specific binding of a nonionic detergent perturbs higher order structure of a therapeutic monoclonal antibody. Journal of pharmaceutical sciences  104(4):1543-1547.

Gruia F, Du J, Santacroce PV, Remmele RL, Jr., Bee JS 2015. Technical decision making with higher order structure data: impact of a formulation change on the higher order structure and stability of a mAb. Journal of pharmaceutical sciences  104(4):1539-1542.

Jiang Y, Li C, Li J, Gabrielson JP, Wen J 2015. Technical decision making with higher order structure data: higher order structure characterization during protein therapeutic candidate screening. Journal of pharmaceutical sciences  104(4):1533-1538.

Wei JY, Bou-Assaf GM, Houde D, Weiskopf A 2015. Technical Decision-Making with Higher Order Structure Data: Detecting Reversible Concentration-Dependent Self-Association in a Monoclonal Antibody and a Preliminary Investigation to Eliminate It. Journal of pharmaceutical sciences  104(11):3984-3989.

Concluding Comments

Bain DL, Brenowitz M, Roberts CJ 2016. An Opportunity for Industry-Academia Partnership: Training the Next Generation of Industrial Researchers in Characterizing Higher Order Protein Structure. Journal of pharmaceutical sciences S0022-3549(16)41665-5. 

Weiss WF 4th, Gabrielson JP, Al-Azzam W, Chen G, Davis DL, Das TK, Hayes DB, Houde D, Singh SK 2016. Technical Decision Making With Higher Order Structure Data: Perspectives on Higher Order Structure Characterization From the Biopharmaceutical Industry. Journal of biopharmaceutical sciences. S0022-3549(16)41695-3.


 

 

 

more Calendar

1/23/2017 » 1/26/2017
CMC Strategy Forum and WCBP 2017

3/14/2017 » 3/17/2017
AT Europe 2017

4/3/2017 » 4/5/2017
HOS 2017

Membership Software Powered by YourMembership  ::  Legal